Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Colbren S. Trogstad-Isaacson"'
Autor:
Robert B. Diasio, Steven M. Offer, Colbren S. Trogstad-Isaacson, Shikshya Shrestha, Timothy J. Hobday, Erin E. Tapper
Publikováno v:
JCO Precision Oncology. :1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77af10b7115dce42c6edad4631d1f1d8
https://doi.org/10.1200/po.18.00179
https://doi.org/10.1200/po.18.00179
Autor:
Robert B. Diasio, Qian Nie, Steven M. Offer, Kelly J. Bouchonville, Erin E. Tapper, Colbren S. Trogstad-Isaacson, Shikshya Shrestha
Publikováno v:
Cancer Research. 78:3893-3893
5-Fluorouracil (5-FU) has remained a widely prescribed anti-cancer drug for decades. However, 5-FU–based treatments show inter-individual variability, with up to 34% of 5-FU–treated patients developing severe (grade 3+) adverse toxicity. Dihydrop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1a9fa8559744744d00d78a770b03581
https://doi.org/10.1158/1538-7445.am2018-3893
https://doi.org/10.1158/1538-7445.am2018-3893
Autor:
Zhiquan Wang, Erin E. Tapper, Qian Nie, Phillip A. Kubica, Steven M. Offer, Kelly J. Bouchonville, Colbren S. Trogstad-Isaacson, Calvin R. Jerde, Shikshya Shrestha, Rentian Wu, Robert B. Diasio
Publikováno v:
Cancer Research. 78:911-911
Colorectal cancer (CRC) is the third most common cancer and is expected to cause approximately 50,000 deaths in the US in 2017. The antimetabolite 5-fluorouracil (5-FU) is the cornerstone of first-line adjuvant chemotherapy regimens for CRC. Resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b5c5c750236f5c8e8dc091814dde382
https://doi.org/10.1158/1538-7445.am2018-911
https://doi.org/10.1158/1538-7445.am2018-911